Merck & Co.
AWARDS
NEWS
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
It was a busy week for clinical trial announcements. Here’s a look.
Merck announced that its proposed treatment Keytruda for non-small cell lung cancer delivered positive results from its Phase III trial.
AstraZeneca and Merck announced their Lynparza drug reduced the risk of death by 32% compared to placebo for specific breast cancer patients.
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
JOBS
IN THE PRESS